Syqe Medical

Executive Summary

Syqe Medical is an Israeli med-tech company that developed SyqeAir, the world's first metered-dose inhaler for medical cannabis. The device delivers precise micro-gram doses of THC and full-spectrum cannabinoids, enabling rapid pain relief with minimal psychoactive side effects. Targeting conditions such as chronic neuropathic pain, endometriosis, fibromyalgia, and palliative care, SyqeAir addresses a significant unmet need for non-opioid pain management. The company has raised $30 million and is at a commercial stage, with potential to disrupt the medical cannabis delivery market. The global medical cannabis market is expanding rapidly, driven by increasing legalization and demand for alternative pain therapies. Syqe Medical's innovative inhalation platform offers dose accuracy and consistency, differentiating it from traditional vaporizers and oral formulations. With a growing body of clinical evidence and regulatory clearances in multiple countries, the company is well-positioned for growth. Strategic partnerships and expansion into new therapeutic areas could further accelerate adoption and revenue generation.

Upcoming Catalysts (preview)

• 2026Regulatory approval in a major market (e.g., FDA or European Medicines Agency)60% success
• 2025Positive results from a pivotal clinical trial in a new indication (e.g., fibromyalgia)65% success
• 2026Strategic partnership or distribution agreement with a large pharmaceutical company50% success